iBio to Report Fiscal 2022 First Quarter Financial Results and Provide Corporate Update on Monday, November 15, 2021
November 08 2021 - 4:30PM
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of
next-generation biopharmaceuticals and pioneer of the sustainable,
plant-based
FastPharming Manufacturing System®,
announced today that it will report its fiscal 2022 first quarter
financial results after market close on Monday, November 15, 2021.
iBio management will host a webcast and conference call at 4:30
p.m. Eastern Time to discuss the results and provide a corporate
update.
The live and archived webcast may be accessed on
the Company’s website at www.ibioinc.com under “News and Events” in
the Investors section. The live call can be accessed by dialing
(833) 672-0651 (domestic) or (929) 517-0227 (international) and
referencing conference code: 7779281.
About iBio, Inc.
iBio is a developer of next-generation
biopharmaceuticals and a pioneer in sustainable, plant-based
biologics manufacturing.
Its FastPharming System® combines
vertical farming, automated hydroponics, and novel glycosylation
technologies to rapidly deliver high-quality monoclonal antibodies,
vaccines, bioinks and other proteins. iBio is developing
proprietary biopharmaceuticals for the treatment of cancers, as
well as fibrotic and infectious diseases. The Company’s
wholly-owned subsidiary, iBio CDMO LLC,
provides FastPharming Contract
Development and Manufacturing Services along with
Glycaneering Development ServicesTM for advanced
recombinant protein design. For more information, visit
www.ibioinc.com.
Contact:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024